Moerae Matrix is a clinical stage biopharmaceutical company focused on the development and delivery of novel therapies for fibrotic and inflammatory diseases. The Company is the leader in developing first-in-class therapeutics that selectively inhibit MAPKAP Kinase 2 (MK2), a protein kinase implicated in both fibrosis and inflammation. The lead program, inhaled MMI-0100, is in development for pulmonary diseases that are characterized by fibrosis and/or inflammation, where direct delivery to target lung tissue may provide significant clinical benefit while minimizing systemic drug exposure. These conditions include Idiopathic Pulmonary Fibrosis (IPF), Chronic Obstructive Pulmonary Disease (COPD) and severe asthma. In addition to lead drug MMI-0100, Moerae’s research and development approach has yielded a pipeline of distinct MK2 inhibitor candidates that may be developed for other diseases in which MK2 dysregulation may play a pathophysiologic role. Moerae has also developed proprietary platform delivery and formulation technologies that will complement and extend the value and utility of the Company’s proprietary MK2 drug portfolio. These technologies also offer a new delivery formulation platform for a broad range of agents.